Physician profile
Abigail Davis
NPI 1477144459
$2,051.70
in general payments reported to CMS, 2019-2025
34 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $941 · 2023: $604 · 2024: $205 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.13 | 2021-2025 | |
| Novo Nordisk INC | $272.31 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $200.60 | 2022-2024 | Omvoh, Mounjaro |
| Novartis Pharmaceuticals Corporation | $136.75 | 2022-2023 | |
| Horizon Therapeutics Plc | $124.50 | 2023 | Tepezza |
| Biohaven Pharmaceutical Holding Company LTD. | $88.09 | 2022 | |
| Amgen INC. | $65.12 | 2022-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $64.14 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $57.85 | 2021-2023 | Recarbrio, Zerbaxa |
| Melinta Therapeutics, LLC | $57.73 | 2023 | Kimyrsa, Rezzayo, Orbactiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.87 | 2021-2023 | Spevigo |
| Abbott Laboratories | $46.86 | 2022-2024 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $43.08 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $38.86 | 2023-2024 | Ultomiris |
| Insulet Corporation | $36.18 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34.42 | 2023-2024 | Injectafer |
| Sumitomo Pharma America, INC. | $31.93 | 2023 | Gemtesa |
| Neurocrine Biosciences, INC. | $29.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $27.99 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $27.19 | 2022 | |
| Revance Therapeutics, INC. | $26.80 | 2025 | Daxxify |
| Genentech USA, INC. | $26.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.66 | 2023 | Gammagard |
| Averitas Pharma INC. | $25.05 | 2024 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $24.53 | 2021 | |
| Pfizer INC. | $24.17 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.84 | 2024 | Saphnelo |
| Lundbeck LLC | $17.62 | 2023 | Vyepti |
| Janssen Pharmaceuticals, INC | $16.89 | 2023 | Xarelto |
| Boston Scientific Corporation | $15.78 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $15.57 | 2023 | Trelegy Ellipta |
| Eisai INC. | $13.38 | 2021 | |
| Astellas Pharma US INC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.